Patients and study design
Data from a prospective, open-labeled, genetically-guided, pilot study,Genetics Of HyperUricemia and Gout Therapy in Hmong (GOUT-H ) (clinicaltrial.gov, NCT02371421) were analyzed. This study was approved by the Human Research Protection Program at the University of Minnesota Institutional Review Board (IRB #1408M53223). Detailed study design was described in previous publication.25 Briefly, 34 Hmong participants with gout and/or hyperuricemia enrolled in the study. After 7 days of allopurinol or febuxostat washout (baseline visit), all the participants took allopurinol 100 mg twice daily for 7 days followed by 150 mg twice daily for 7 days. At the follow-up visit (2 weeks after the baseline visit), participants took the final dose of allopurinol.
Blood samples were collected at the baseline and follow-up visits to measure SU and serum creatinine after overnight fasting for 10 hours. Additionally, blood and urine samples were collected at 0, 2, 4, and 6-hours post-allopurinol dose at the follow-up visit to measure oxypurinol concentrations.